
Talazoparib TALAPRO-2



Talazoparib TALAPRO-2 Talazoparib TALAPRO-2 PRFLIMINARY SCORE **FINAL SCORE CURATIVE CURATIVE NON-CURATIVE NON-CURATIVE** Overall Survival **ADJUSTMENTS** Quality of life Progression-Free Survival QoL data pending Serious and disabling adverse effects Overall Response Rate / Duration of Response Other adjustments INFORMATION Tumour type: Genitourinary Cancers mutated metastatic castration-resistant prostate cancer (mCRPC). Experimental Arm: Talazoparib + Enzalutamide Control Arm: Placebo plus enzalutamide





© 2023 | European Society for Medical Oncology | ESMO - MCBS 1.1 | All rights reserved worldwide.